Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
2008 1
2009 1
2010 1
2011 1
2012 1
2013 1
2014 1
2016 3
2017 1
2019 3
2020 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Molecular genetics of childhood, adolescent and young adult non-Hodgkin lymphoma.
Miles RR, Shah RK, Frazer JK. Miles RR, et al. Br J Haematol. 2016 May;173(4):582-96. doi: 10.1111/bjh.14011. Epub 2016 Mar 11. Br J Haematol. 2016. PMID: 26969846 Free PMC article. Review.
Certain recurrent molecular genetic abnormalities in NHL underlie molecular pathogenesis and/or are associated with prognosis or represent potential therapeutic targets. Most molecular genetic studies of B- and T-NHL have been performed on adult patient samples, and the re …
Certain recurrent molecular genetic abnormalities in NHL underlie molecular pathogenesis and/or are associated with prognosis or repr …
Targeting childhood, adolescent and young adult non-Hodgkin lymphoma: therapeutic horizons.
Galardy PJ, Bedekovics T, Hermiston ML. Galardy PJ, et al. Br J Haematol. 2016 May;173(4):625-36. doi: 10.1111/bjh.14016. Epub 2016 Mar 27. Br J Haematol. 2016. PMID: 27019108 Free article. Review.
While advances in the use of conventional cytotoxic agents have led to dramatic improvements in survival, these cures are associated with significant acute and long-term toxicities. Moreover, the prognosis for CAYA patients with relapsed or refractory NHL remains dismal, w …
While advances in the use of conventional cytotoxic agents have led to dramatic improvements in survival, these cures are associated with si …
Paediatric non-Hodgkin lymphoma - perspectives in translational biology.
Shiramizu B, Mussolin L, Woessmann W, Klapper W. Shiramizu B, et al. Br J Haematol. 2016 May;173(4):617-24. doi: 10.1111/bjh.14009. Epub 2016 Mar 24. Br J Haematol. 2016. PMID: 27009921 Free PMC article. Review.
In spite of these successes, new frontiers are being paved to improve the prognosis for those who relapse or have resistant disease. This review summarizes some of the novel approaches and ideas in NHL monitoring, diagnosis and treatment as discussed at the 5th Internation …
In spite of these successes, new frontiers are being paved to improve the prognosis for those who relapse or have resistant disease. …
Advances in cellular and humoral immunotherapy - implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma.
Chu Y, Gardenswartz A, Termuhlen AM, Cairo MS. Chu Y, et al. Br J Haematol. 2019 Jun;185(6):1055-1070. doi: 10.1111/bjh.15753. Epub 2019 Jan 6. Br J Haematol. 2019. PMID: 30613939 Free PMC article. Review.
Patients with relapsed, refractory or advanced stage B non-Hodgkin lymphoma (NHL) continue to have a dismal prognosis. This review summarises current and novel cellular and immunotherapy for these high-risk populations, including haematopoietic stem cell transplant, bispec …
Patients with relapsed, refractory or advanced stage B non-Hodgkin lymphoma (NHL) continue to have a dismal prognosis. This review su …
Guideline Concordance of Treatment and Outcomes Among Adult Non-Hodgkin Lymphoma Patients in Sub-Saharan Africa: A Multinational, Population-Based Cohort.
Mezger NCS, Hämmerl L, Griesel M, Seraphin TP, Joko-Fru YW, Feuchtner J, Zietsman A, Péko JF, Tadesse F, Buziba NG, Wabinga H, Nyanchama M, Chokunonga E, Kéita M, N'da G, Lorenzoni CF, Akele-Akpo MT, Mezger JM, Binder M, Liu B, Bauer M, Henke O, Jemal A, Kantelhardt EJ. Mezger NCS, et al. Oncologist. 2023 Nov 2;28(11):e1017-e1030. doi: 10.1093/oncolo/oyad157. Oncologist. 2023. PMID: 37368350 Free PMC article.
Prognostic Factors and Outcomes of Adult Lymphoblastic Lymphoma in the United States.
El-Fattah MA. El-Fattah MA. Clin Lymphoma Myeloma Leuk. 2017 Aug;17(8):498-505.e6. doi: 10.1016/j.clml.2017.05.016. Epub 2017 Jun 6. Clin Lymphoma Myeloma Leuk. 2017. PMID: 28647403
The aim of the present analysis was to characterize the clinical features and histologic subtypes and to assess the clinical prognostic factors for 696 adult patients with LL, the largest epidemiologic sample to date. ...Multivariate analysis identified age, race, and radi …
The aim of the present analysis was to characterize the clinical features and histologic subtypes and to assess the clinical prognostic …
Complications and hospital costs during hematopoietic stem cell transplantation for non-Hodgkin lymphoma in the United States.
Cho SK, McCombs J, Punwani N, Lam J. Cho SK, et al. Leuk Lymphoma. 2019 Oct;60(10):2464-2470. doi: 10.1080/10428194.2019.1581932. Epub 2019 Mar 8. Leuk Lymphoma. 2019. PMID: 30848975
Using the National Inpatient Sample (NIS) database from 2012-2014, we identified 1832 adult non-Hodgkin lymphoma (NHL) patients who received autologous or allogeneic HSCT and examined complications as predictors of hospital cost. Complications occurred in >70% of patien …
Using the National Inpatient Sample (NIS) database from 2012-2014, we identified 1832 adult non-Hodgkin lymphoma (NHL) patients who received …
Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles.
Cillessen SA, Meijer CJ, Notoya M, Ossenkoppele GJ, Oudejans JJ. Cillessen SA, et al. J Pathol. 2010 Apr;220(5):509-20. doi: 10.1002/path.2670. J Pathol. 2010. PMID: 20087881 Review.
The development of molecules targeting these apoptosis inhibitors provides a very promising opportunity to specifically target tumour cells without toxicity to non-malignant cells in DLBCL patients. Sensitivity for most of these antagonists can be predicted based on biolog …
The development of molecules targeting these apoptosis inhibitors provides a very promising opportunity to specifically target tumour cells …
CD56-positive diffuse large B-cell lymphoma/leukemia with BCL6/MYC double-hit and multiple gene mutations: an indicator of poor prognosis?
Liu Y, Shen J, Awal Issah M, Liu T, Zhou H, Fu H. Liu Y, et al. J Int Med Res. 2020 May;48(5):300060520918087. doi: 10.1177/0300060520918087. J Int Med Res. 2020. PMID: 32363958 Free PMC article. Review.
Diffuse large B-cell lymphoma (DLBCL) is the most common adult non-Hodgkin lymphoma (NHL) and is highly invasive, with a poor prognosis. The main clinical treatment for DLBCL involves chemotherapy or a combination of chemotherapy and targeted drugs. CD56 expression is cons …
Diffuse large B-cell lymphoma (DLBCL) is the most common adult non-Hodgkin lymphoma (NHL) and is highly invasive, with a poor prognosis …
16 results